非诺贝特与阿托伐他汀联合治疗糖尿病合并高血脂的效果分析(1)
【摘要】 目的 研究非诺贝特与阿托伐他汀联合治疗糖尿病合并高血脂的效果。方法 34例糖尿病合并高血脂患者， 采用随机抽签法分为实验组和对照组， 每组17例。对照组患者采用非诺贝特单独治疗， 实验组患者采用非诺贝特联合阿托伐他汀治疗。对比两组患者治疗效果、不良反应发生情况及治疗前后血糖、血脂指标水平。结果 实验组患者治疗总有效率为94.12%， 高于对照组的64.71%， 差异具有统计学意义(P<0.05)。治疗前， 两组患者空腹血糖(FPG)、餐后2 h血糖(2 h PG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平对比差異无统计学意义(P>0.05)。治疗后， 两组患者FPG、2 h PG、LDL-C水平均较本组治疗前降低， HDL-C水平较本组治疗前升高， 差异具有统计学意义(P<0.05)。治疗后， 两组患者FPG、2 h PG、LDL-C水平对比差异无统计学意义(P>0.05);实验组患者HDL-C水平高于对照组， 差异具有统计学意义(P<0.05)。实验组患者不良反应发生率为23.53%， 与对照组的17.65%对比差异无统计学意义(P>0.05)。结论 非诺贝特与阿托伐他汀联合应用于糖尿病合并高血脂患者的治疗， 患者的血糖、血脂等得到较好的控制， 临床症状得到有效改善， 有部分不良反应发生， 但发生率低， 值得临床应用。
【关键词】 非诺贝特;阿托伐他汀;糖尿病;高血脂;效果
DOI：10.14163/j.cnki.11-5547/r.2019.17.003
Effect analysis of fenofibrate combined with atorvastatin in the treatment of diabetes mellitus with hyperlipidemia LI Lan-qing. Beijing Fengtai District Youanmen Community Health Service Center， Beijing 100071， China
【Abstract】 Objective To study the effect of fenofibrate combined with atorvastatin in the treatment of diabetes mellitus with hyperlipidemia. Methods A total of 34 patients with diabetes mellitus with hyperlipidemia were divided by random lottery method into experimental group and control group， with 17 cases in each group. The control group was treated with fenofibrate only， and the experimental group was treated with fenofibrate combined with atorvastatin. Comparison were made on treatment effect， occurrence of adverse reactions， blood glucose and lipid levels before and after treatment between the two groups. Results The experimental group had higher total treatment effective rate as 94.12% than 64.71% in the control group， and the difference was statistically significant (P<0.05). Before treatment， both groups had no statistically significant difference in fasting plasma glucose (FPG)， postprandial 2 h plasma glucose (2 h PG)， low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) levels (P>0.05). After treatment， both groups had lower FPG， 2 h PG and LDL-C than those before treatment， and higher HDL-C than that before treatment. Their difference was statistically significant (P<0.05). After treatment， both groups had no statistically significant difference in FPG， 2 h PG and LDL-C (P>0.05). The experimental group had higher HDL-C than the control group， and the difference was statistically significant (P<0.05). The experimental group had no statistically significant difference in incidence of adverse reactions as 23.53%， comparing with 17.65% in the control group (P>0.05). Conclusion Fenofibrate combined with atorvastatin can better control blood glucose and lipid of patients with diabetes mellitus and hyperlipidemia， and effectively improve their clinical symptoms. Some adverse reactions occur， but the incidence is low. It is worthy of clinical application.(李兰卿)